Skip to main content

Advertisement

SpringerLink
Log in

Update on clinical and mechanistic aspects of paraneoplastic syndromes

  • CLINICAL
  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Many patients with cancer are afflicted with an array of severe ailments caused by remote effects of the neoplasm on distant organs, which it has not invaded or colonized. The growing local tumor dominates attention, but invisible chemical and cellular components released by this parasitic neoplastic growth can operate below the threshold of detection to derange feedback loops coordinating essential physiological functions. Ultimately, these changes cause serious signs and symptoms, collectively described as paraneoplastic syndromes (PNSs), which significantly diminish the patient’s quality of life. PNS can appear before, or after, detection of the cancer and are sometimes surprising or even bizarre. The patterns of clinical changes seen in these patients are caused by a range of mechanisms that reveal intricate networks of communications between different body systems, normally utilized for healthy function. For example, these disorders demonstrate that (1) hormones, peptides, and other long- and short-range signaling molecules produced by the tumor and (2) immune reactions to tumor-related antigens, can mediate diverse destabilizing effects. However, comparative analysis of numerous PNS reveals valuable information indicating that the primary pathogenetic events instigating these disturbances are much more fundamental. This article provides an overview of the diverse clinical manifestations of paraneoplastic disorders, with representative examples and presents evidence that inappropriate gene expression in the tumor, caused by loss of regulatory control, is a novel unifying explanation for such wide effects of the neoplasm on the host. It also discusses treatment options and issues relating to conducting randomized clinical trials on these disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Tarin, D., (2013). Role of the host stroma in cancer and its therapeutic significance. Cancer Metastasis Reviews. doi:10.1007/s10555-013-9438-4

  2. Graus, F., Delattre, J. Y., Antoine, J. C., et al. (2004). Recommended diagnostic criteria for paraneoplastic neurological syndromes. Journal of Neurology, Neurosurgery, and Psychiatry, 75, 1135–1140.

    Article  PubMed  CAS  Google Scholar 

  3. Voltz, R. (2002). Paraneoplastic neurological syndromes: An update on diagnosis, pathogenesis, and therapy. Lancet Neurology, 1, 294–305.

    Article  PubMed  Google Scholar 

  4. Trousseau, A. (1872) Lectures on clinical medicine. Lecture XLV, delivered at the Hotel-Dieu, Paris, Volume 5 (Translated by Sir John Rose Cormack from the edition of 1868) (pp. 281–332). Philadelphia: Lindsay and Blakiston

  5. Darnell, R. E., & Posner, J. B. (2011). Paraneoplastic syndromes (p. 496). Oxford: Oxford University Press.

    Google Scholar 

  6. Azzopardi, J. G. (1966). Systemic effects of neoplasia. In C. V. Harrison (Ed.), Recent advances in pathology (pp. 98–184). London: Churchill.

    Google Scholar 

  7. Pelosof, L. C., & Gerber, D. E. (2010). Paraneoplastic syndromes: An approach to diagnosis and treatment. Mayo Clinic Proceedings Mayo Clinic, 85, 838–854.

    Article  PubMed  Google Scholar 

  8. Varki, A. (2007). Trousseau’s syndrome: Multiple definitions and multiple mechanisms. Blood, 110, 1723–1729.

    Article  PubMed  CAS  Google Scholar 

  9. Zhao, R., Xing, S., Li, Z., et al. (2005). Identification of an acquired JAK2 mutation in polycythemia vera. The Journal of Biological Chemistry, 280, 22788–22792.

    Article  PubMed  CAS  Google Scholar 

  10. Eubanks, L. E., McBurney, E., & Reed, R. (2001). Erythema gyratum repens. The American Journal of the Medical Sciences, 321, 302–305.

    Article  PubMed  CAS  Google Scholar 

  11. Gore, M., & Winters, M. E. (2011). Erythema gyratum repens: A rare paraneoplastic rash. The Western Journal of Emergency Medicine, 12, 556–558.

    PubMed  Google Scholar 

  12. Anderson, S. H., Hudson-Peacock, M., & Muller, A. F. (1999). Malignant acanthosis nigricans: Potential role of chemotherapy. The British Journal of Dermatology, 141, 714–716.

    Article  PubMed  CAS  Google Scholar 

  13. Matsuoka, L. Y., Wortsman, J., & Goldman, J. (1993). Acanthosis nigricans. Clinics in Dermatology, 11, 21–25.

    Article  PubMed  CAS  Google Scholar 

  14. Ellis, D. L., Kafka, S. P., Chow, J. C., et al. (1987). Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Trelat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. The New England Journal of Medicine, 317, 1582–1587.

    Article  PubMed  CAS  Google Scholar 

  15. Koyama, S., Ikeda, K., Sato, M., et al. (1997). Transforming growth factor-alpha (TGF alpha)-producing gastric carcinoma with acanthosis nigricans: An endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. Journal of Gastroenterology, 32, 71–77.

    Article  PubMed  CAS  Google Scholar 

  16. Azar, L., & Khasnis, A. (2013). Paraneoplastic rheumatologic syndromes. Current Opinion in Rheumatology, 25, 44–49.

    Article  PubMed  Google Scholar 

  17. Kuo, C. F., See, L. C., Yu, K. H., et al. (2011). Incidence, cancer risk and mortality of dermatomyositis and polymyositis in Taiwan: A nationwide population study. The British Journal of Dermatology, 165, 1273–1279.

    Article  PubMed  Google Scholar 

  18. Zhang, W., Jiang, S. P., & Huang, L. (2009). Dermatomyositis and malignancy: A retrospective study of 115 cases. European Review for Medical and Pharmacological Sciences, 13, 77–80.

    PubMed  Google Scholar 

  19. Casciola-Rosen, L., Nagaraju, K., Plotz, P., et al. (2005). Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. The Journal of Experimental Medicine, 201, 591–601.

    Article  PubMed  CAS  Google Scholar 

  20. Ellison, M. L. (1977). Cell differentiation and the biological significance of inappropriate tumour products. Proceedings of the Royal Society of Medicine, 70, 845–850.

    PubMed  CAS  Google Scholar 

  21. Voyadzis, J. M., Guttman-Bauman, I., Santi, M., et al. (2004). Hypothalamic hamartoma secreting corticotropin-releasing hormone. Case report. Journal of Neurosurgery, 100, 212–216.

    PubMed  Google Scholar 

  22. Grill, V., & Martin, T. J. (2000). Hypercalcemia of malignancy. Reviews in Endocrine & Metabolic Disorders, 1, 253–263.

    Article  CAS  Google Scholar 

  23. Lumachi, F., Brunello, A., Roma, A., et al. (2009). Cancer-induced hypercalcemia. Anticancer Research, 29, 1551–1555.

    PubMed  CAS  Google Scholar 

  24. Philbrick, W. M., Wysolmerski, J. J., Galbraith, S., et al. (1996). Defining the roles of parathyroid hormone-related protein in normal physiology. Physiological Reviews, 76, 127–173.

    PubMed  CAS  Google Scholar 

  25. Davidson, L. A., Black, M., Carey, F. A., et al. (1996). Lung tumours immunoreactive for parathyroid hormone related peptide: Analysis of serum calcium levels and tumour type. The Journal of Pathology, 178, 398–401.

    Article  PubMed  CAS  Google Scholar 

  26. Komminoth, P., Heitz, P. U., & Roth, J. (1999). Human insulinomas: Clinical, cellular, and molecular aspects. Endocrine Pathology, 10, 269–281.

    Article  PubMed  CAS  Google Scholar 

  27. Lloyd, R. V., Erickson, L. A., Nascimento, A. G., et al. (1999). Neoplasms causing nonhyperinsulinemic hypoglycemia. Endocrine Pathology, 10, 291–297.

    Article  PubMed  Google Scholar 

  28. Sorensen, J. B., Andersen, M. K., & Hansen, H. H. (1995). Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. Journal of Internal Medicine, 238, 97–110.

    Article  PubMed  CAS  Google Scholar 

  29. Dalmau, J., & Rosenfeld, M. R. (2008). Paraneoplastic syndromes of the CNS. Lancet Neurology, 7, 327–340.

    Article  PubMed  Google Scholar 

  30. Darnell, R., & Posner, J. (2011). Paraneoplastic syndromes. Oxford: Oxford University Press.

    Google Scholar 

  31. Toothaker, T. B., & Rubin, M. (2009). Paraneoplastic neurological syndromes: A review. The Neurologist, 15, 21–33.

    Article  PubMed  Google Scholar 

  32. Corsellis, J. A., Goldberg, G. J., & Norton, A. R. (1968). “Limbic encephalitis” and its association with carcinoma. Brain Journal of Neurology, 91, 481–496.

    Article  CAS  Google Scholar 

  33. Gultekin, S. H., Rosenfeld, M. R., Voltz, R., et al. (2000). Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. A Journal of Neurology, 123(Pt 7), 1481–1494.

    Google Scholar 

  34. Giometto, B., Marchiori, G. C., Nicolao, P., et al. (1997). Sub-acute cerebellar degeneration with anti-Yo autoantibodies: immunohistochemical analysis of the immune reaction in the central nervous system. Neuropathology and Applied Neurobiology, 23, 468–474.

    Article  PubMed  CAS  Google Scholar 

  35. Hildebrand, J., & Baleriaux. (2002). Cerebellar disorders in cancer. In M. Manto & M. Pandolfo (Eds.), The cerebellum and its disorders. Oxford: Oxford University Press.

    Google Scholar 

  36. Verschuuren, J., Chuang, L., Rosenblum, M. K., et al. (1996). Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo-associated paraneoplastic cerebellar degeneration. Acta neuropathologica, 91, 519–525.

    Article  PubMed  CAS  Google Scholar 

  37. Graus, F., & Dalmau, J. (2012). Paraneoplastic neurological syndromes. Current Opinion in Neurology, 25, 795–801.

    Article  PubMed  CAS  Google Scholar 

  38. Sakai, K., Mitchell, D. J., Tsukamoto, T., et al. (1990). Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. Annals of Neurology, 28, 692–698.

    Google Scholar 

  39. Candler, P. M., Hart, P. E., Barnett, M., et al. (2004). A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. Journal of Neurology, Neurosurgery, and Psychiatry, 75, 1411–1415.

    Article  PubMed  CAS  Google Scholar 

  40. Greenlee, J. E. (2010). Treatment of paraneoplastic neurologic disorders. Current Treatment Options in Neurology, 12, 212–230.

    Article  PubMed  Google Scholar 

  41. Harbour, R., & Miller, J. (2001). A new system for grading recommendations in evidence based guidelines. BMJ, 323, 334–336.

    Article  PubMed  CAS  Google Scholar 

  42. Voltz, R., Dalmau, J., Posner, J. B., et al. (1998). T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology, 51, 1146–1150.

    Article  PubMed  CAS  Google Scholar 

  43. Suzuki, H., Asakawa, A., Amitani, H., et al. (2013). Cancer cachexia-pathophysiology and management. Journal of Gastroenterology, 48, 574–594.

    Article  PubMed  CAS  Google Scholar 

  44. Braik, T., Evans, A. T., Telfer, M., et al. (2010). Paraneoplastic neurological syndromes: unusual presentations of cancer. A practical review. The American Journal of the Medical Sciences, 340, 301–308.

    Article  PubMed  Google Scholar 

  45. Kim, Y. I. (1986). Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle & Nerve, 9, 523–530.

    Article  CAS  Google Scholar 

  46. Newsom-Davis, J. (2001). Lambert–Eaton myasthenic syndrome. Current Treatment Options in Neurology, 3, 127–131.

    Article  PubMed  Google Scholar 

  47. Koike, H., & Sobue, G. (2013). Wide range of clinicopathological features in immune-mediated autonomic neuropathies. Cinical and Experimental Neuroimmunology, 3, 1–14.

    Google Scholar 

  48. Lien, Y. H., & Lai, L. W. (2011). Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nature Reviews Nephrology, 7, 85–95.

    Article  PubMed  CAS  Google Scholar 

  49. Bacchetta, J., Juillard, L., Cochat, P., et al. (2009). Paraneoplastic glomerular diseases and malignancies. Critical Reviews in Oncology/Hematology, 70, 39–58.

    Article  PubMed  Google Scholar 

  50. Lewis, M. G., Loughridge, L. W., & Phillips, T. M. (1971). Immunological studies in nephrotic syndrome associated with extrarenal malignant disease. Lancet, 2, 134–135.

    Article  PubMed  CAS  Google Scholar 

  51. Loughridge, L. W., & Lewis, M. G. (1971). Nephrotic syndrome in malignant disease of non-renal origin. Lancet, 1, 256–258.

    Article  PubMed  CAS  Google Scholar 

  52. Gagliano, R. G., Costanzi, J. J., Beathard, G. A., et al. (1976). The nephrotic syndrome associated with neoplasia: an unusual paraneoplastic syndrome. Report of a case and review of the literature. The American journal of medicine, 60, 1026–1031.

    Article  PubMed  CAS  Google Scholar 

  53. Drachman, D. B., Adams, R. N., Josifek, L. F., et al. (1982). Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. The New England journal of medicine, 307, 769–775.

    Article  PubMed  CAS  Google Scholar 

  54. Hohlefeld, R., Werkele, H., & Marx, A. (2012) The immuno-pathogenesis of myasthenia gravis, Chapter 3. In A. G Engel (Ed.), Myasthenia Gravis and Myasthenic Disorders, 2nd edn (pp. 60–84). Oxford: Oxford University Press

  55. Zell, J. A., & Chang, J. C. (2005). Neoplastic fever: A neglected paraneoplastic syndrome. Supportive Care in Cancer, 13, 870–877.

    Article  PubMed  Google Scholar 

  56. Tarin, D. (2012). Inappropriate gene expression in human cancer and its far-reaching biological and clinical significance. Cancer Metastasis Reviews, 31, 21–39.

    Article  PubMed  CAS  Google Scholar 

  57. Muggia, F. M., & Ultmann, J. E. (1971). Glomerulonephritis or nephrotic syndrome in malignant lymphoma, reticulum-cell type. Lancet, 1, 805.

    Article  PubMed  CAS  Google Scholar 

  58. Giometto, B., Vitaliani, R., Lindeck-Pozza, E., et al. (2012). Treatment for paraneoplastic neuropathies. Cochrane database of systematic reviews, 12, CD007625.

    PubMed  Google Scholar 

  59. Pakozdy, A., Halasz, P., Klang, A., et al. (2013). Suspected limbic encephalitis and seizure in cats associated with voltage-gated potassium channel (VGKC) complex antibody. Journal of Veterinary Internal Medicine / American College of Veterinary Internal Medicine, 27, 212–214.

    Article  PubMed  CAS  Google Scholar 

  60. Turek, M. M. (2003). Cutaneous paraneoplastic syndromes in dogs and cats: A review of the literature. Veterinary Dermatology, 14, 279–296.

    Article  PubMed  Google Scholar 

  61. Fedorchuk, O. G., Pyaskovskaya, O. M., Skivka, L. M., et al. (2012). Paraneoplastic syndrome in mice bearing high-angiogenic variant of Lewis lung carcinoma: relations with tumor derived VEGF. Cytokine, 57, 81–88.

    Article  PubMed  CAS  Google Scholar 

  62. Lucke, B., & Berwick, M. (1954). Catalase activity of liver and kidney in frogs with spontaneous renal carcinoma. The Journal of Experimental Medicine, 100, 125–133.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The author acknowledges with gratitude the valuable comments, suggestions, and discussions provided by D. L. Darling, MD and G. G.Miklos, PhD.

Conflict of interest

No specific funding sources or financial disclosures.

Author information

Authors and Affiliations

  1. Moores Cancer Center and Department of Pathology, University of California, San Diego, 3855 Health Sciences Drive, MC0803, La Jolla, CA, 92106, USA

    David Tarin

Authors
  1. David Tarin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Tarin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tarin, D. Update on clinical and mechanistic aspects of paraneoplastic syndromes. Cancer Metastasis Rev 32, 707–721 (2013). https://doi.org/10.1007/s10555-013-9446-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-013-9446-4

Keywords

Search

Navigation